Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Tau biomarkers

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

ABSTRACT Background Cardiovascular health factors are associated with cognitive decline and risk of dementia, including Alzheimer disease (AD); however, this has been mostly studied in late life. We investigated whether vascular and lifestyle factors are associated with AD plasma and imaging biomarkers in midlife. Methods We investigated 1,406 participants from the Coronary Artery Risk Development in Young Adults (CARDIA) study with information on vascular and lifestyle factors framed from the American Heart Association (AHA) “life’s essential 8” (LE8) guidelines for cardiovascular health at early midlife (mean age 45.0 ± SD 3.6) and AD biomarkers in late midlife (mean age 60 ± SD 3.5).

What this study adds

Evidence grade: Low

The record lists 1,406 participants. It examines associations with biomarkers and does not show that any intervention treats, cures, or prevents Alzheimer's disease. Reported effect size: 67.9%; 12.6%.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Dintica, C. S., Jiang, X., Shaw, L. M., Bryan, R. N., & Yaffe, K. (2026). Cardiovascular Health at Midlife and Alzheimer Disease Biomarkers. medRxiv. https://doi.org/10.64898/2026.04.15.26350968

Vancouver

Dintica CS, Jiang X, Shaw LM, Bryan RN, Yaffe K. Cardiovascular Health at Midlife and Alzheimer Disease Biomarkers. medRxiv. 2026. doi:10.64898/2026.04.15.26350968.

BibTeX

@article{dintica2026-37136884,
  author  = {Dintica, C. S. and Jiang, X. and Shaw, L. M. and Bryan, R. N. and Yaffe, K.},
  title   = {{Cardiovascular Health at Midlife and Alzheimer Disease Biomarkers}},
  journal = {medRxiv},
  year    = {2026},
  doi     = {10.64898/2026.04.15.26350968},
  url     = {https://doi.org/10.64898/2026.04.15.26350968}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

Among 1,406 participants in the CARDIA study, this work investigated whether cardiovascular health factors at early midlife, framed by the American Heart Association's life's essential 8 guidelines, were associated with Alzheimer's disease plasma and imaging biomarkers at late midlife. It examines associations with biomarkers and does not show that any intervention treats, cures, or prevents Alzheimer's disease.

Study details

How this study scored 16/100
How this study's score is builtJournal tier 2 of 10; Journal's citation record 0 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 4 of 10; How recent 5 of 5; Sample size 3 of 4; Effect reported 2 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 1 of 7; Citations per year 0 of 5; Impact for its field and year left out, no data; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 4 of 4; Institution's track record 2 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 1 of 2; Free to read 0 of 2. 30 of the 94 points it could be judged on, which is 32 of 100. Raw total 32 of 100, shown as 16 because this is not a peer-reviewed research article.raw total 32 of 100capped at 16 — hatched points do not count

Preprint — not yet peer-reviewed. It scored 32 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for study design and randomized / blinded because the record does not state it. We have no data on impact for its field and year, so that was left out: it earned 30 of the 94 points we could judge it on, which is 32 out of 100.

ComponentPointsWhy
Journal tier 2 / 10 Tier 4 — not a peer-reviewed journal (medRxiv)
Journal's citation record 0 / 4 Not a journal article, so the journal's record does not count
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 4 / 10 Preprint — not yet peer-reviewed. Hosted on a preprint server.
How recent 5 / 5 2026 — within 1 year(s) of the newest study here
Sample size 3 / 4 1,406 participants
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 1 / 7 Cited 1 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.5 citations a year over 2 year(s) since 2026
Impact for its field and year — / 6 No field-weighted citation impact (OpenAlex has none yet) — left out of this score
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author Kristine S. Yaffe: h-index 155 (OpenAlex, whole career)
Institution's track record 2 / 3 University of California, San Francisco: institution h-index 1,915 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 4 institution(s) in 1 country
Indexed in PubMed 1 / 2 Not in PubMed, but has a DOI
Free to read 0 / 2 Behind a paywall — scores zero
Points 30 / 94 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 30 of the 94 points we could judge it on is 32 out of 100.
Total 32 / 100 Capped to 16 because this is not a peer-reviewed article.

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Tau biomarkers from nearby years

Also tagged “cerebrospinal”

820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Tau biomarkers

See all studies in Tau biomarkers →